| 臺大學術典藏 |
2022-04-15T02:42:33Z |
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
|
Harbeck, N; Rastogi, P; Martin, M; Tolaney, S M; Shao, Z M; Fasching, P A; CHIUN-SHENG HUANG; Jaliffe, G G; Tryakin, A; Goetz, M P; Rugo, H S; Senkus, E; Testa, L; Andersson, M; Tamura, K; Del Mastro, L; Steger, G G; Kreipe, H; Hegg, R; Sohn, J; Guarneri, V; Cortés, J; Hamilton, E; André, V; Wei, R; Barriga, S; Sherwood, S; Forrester, T; Munoz, M; Shahir, A; San Antonio, B; Nabinger, S C; Toi, M; Johnston, S R D; O'Shaughnessy, J |
| 臺大學術典藏 |
2022-03-10T06:15:01Z |
Genomic profiling of premenopausal HR+ and HER2�V metastatic breast cancer by circulating tumor DNA and association of genetic alterations with therapeutic response to endocrine therapy and ribociclib
|
Bardia A.; Su F.; Solovieff N.; Im S.-A.; Sohn J.; Lee K.S.; Campos-Gomez S.; Jung K.H.; Colleoni M.; V?zquez R.V.; Franke F.; Hurvitz S.; Harbeck N.; Chow L.; Taran T.; Lorenc K.R.; Babbar N.; Tripathy D.; YEN-SHEN LU |
| 臺大學術典藏 |
2022-03-10T06:15:00Z |
Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs
|
Hata T.; Nakamura K.; Yonemori K.; Noguchi E.; Watanabe M.; Sohn J.; YEN-SHEN LU; Yap Y.-S.; Tamura K.; Fujiwara Y. |
| 臺大學術典藏 |
2021-03-10T02:36:30Z |
A phase ib study of alpelisib or buparlisib combined with tamoxifen plus goserelin in premenopausal women with HR-positive HER2-negative advanced breast cancer
|
YEN-SHEN LU; Lee K.S.; Chao T.-Y.; Tseng L.-M.; Chitapanarux I.; Chen S.-C.; Liu C.-T.; Sohn J.; Kim J.H.; Chang Y.-C.; Yang Y.; Shotelersuk K.; Jung K.H.; Valenti R.; Slader C.; Gao M.; Park Y.H. |
| 臺大學術典藏 |
2020-08-13T06:33:32Z |
Ramucirumab safety in East Asian patients: A meta-analysis of six global, randomized, double-blind, placebo-controlled, phase III clinical trials
|
Zhang Y.; Sohn J.; Cheng R.; Yamazaki K.; Kim S.-W.; Chao Y.; Lee K.-W.; JIN-YUAN SHIH; Kudo M.; Kim T.-W.; Muro K.; Yen C.-J.; Yen C.-J.;Muro K.;Kim T.-W.;Kudo M.;Jin-Yuan Shih;Lee K.-W.;Chao Y.;Kim S.-W.;Yamazaki K.;Sohn J.;Cheng R.;Zhang Y.;Binder P.;Mi G.;Orlando M.;Chung H.C.; Binder P.; Mi G.; Orlando M.; Chung H.C. |
| 臺大學術典藏 |
2020-08-13T06:33:32Z |
Ramucirumab safety in East Asian patients: A meta-analysis of six global, randomized, double-blind, placebo-controlled, phase III clinical trials
|
Zhang Y.; Sohn J.; Cheng R.; Yamazaki K.; Kim S.-W.; Chao Y.; Lee K.-W.; JIN-YUAN SHIH; Kudo M.; Kim T.-W.; Muro K.; Yen C.-J.; Yen C.-J.;Muro K.;Kim T.-W.;Kudo M.;Jin-Yuan Shih;Lee K.-W.;Chao Y.;Kim S.-W.;Yamazaki K.;Sohn J.;Cheng R.;Zhang Y.;Binder P.;Mi G.;Orlando M.;Chung H.C.; Binder P.; Mi G.; Orlando M.; Chung H.C. |
| 臺大學術典藏 |
2020-05-25T06:51:46Z |
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|
Franke F; Bardia A; Harbeck N; Hurvitz S.A; Chow L; Sohn J; Lee K.S; Campos-Gomez S; Villanueva Vazquez R; Jung K.H; Babu K.G; Wheatley-Price P; De Laurentiis M; Im Y.-H; Kuemmel S; El-Saghir N; Liu M.-C; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; YEN-SHEN LU; Colleoni M; Im S.-A; Tripathy D; Tripathy D;Im S.-A;Colleoni M;Franke F;Bardia A;Harbeck N;Hurvitz S.A;Chow L;Sohn J;Lee K.S;Campos-Gomez S;Villanueva Vazquez R;Jung K.H;Babu K.G;Wheatley-Price P;De Laurentiis M;Im Y.-H;Kuemmel S;El-Saghir N;Liu M.-C;Carlson G;Hughes G;Diaz-Padilla I;Germa C;Hirawat S;Yen-Shen Lu |
| 臺大學術典藏 |
2020-05-25T06:51:46Z |
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|
Franke F; Bardia A; Harbeck N; Hurvitz S.A; Chow L; Sohn J; Lee K.S; Campos-Gomez S; Villanueva Vazquez R; Jung K.H; Babu K.G; Wheatley-Price P; De Laurentiis M; Im Y.-H; Kuemmel S; El-Saghir N; Liu M.-C; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; YEN-SHEN LU; Colleoni M; Im S.-A; Tripathy D; Tripathy D;Im S.-A;Colleoni M;Franke F;Bardia A;Harbeck N;Hurvitz S.A;Chow L;Sohn J;Lee K.S;Campos-Gomez S;Villanueva Vazquez R;Jung K.H;Babu K.G;Wheatley-Price P;De Laurentiis M;Im Y.-H;Kuemmel S;El-Saghir N;Liu M.-C;Carlson G;Hughes G;Diaz-Padilla I;Germa C;Hirawat S;Yen-Shen Lu |
| 臺大學術典藏 |
2020-05-25T06:51:44Z |
Ribociclib (RIB) + non-steroidal aromatase inhibitor (NSAI) + goserelin in premenopausal Asian women with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from the randomized phase III MONALEESA-7 study
|
Im S.-A;Sohn J;Tripathy D;Chow L;Lee K.S;Jung K.H;Babu G;Im Y.-H;El Saghir N;Liu M.-C;Diaz-Padilla I;Alam J;Kong O;Miller M;Yen-Shen Lu; Im S.-A; Sohn J; Tripathy D; Chow L; Lee K.S; Jung K.H; Babu G; Im Y.-H; El Saghir N; Liu M.-C; Diaz-Padilla I; Alam J; Kong O; Miller M; YEN-SHEN LU |
| 臺大學術典藏 |
2020-05-25T06:51:44Z |
Ribociclib (RIB) + non-steroidal aromatase inhibitor (NSAI) + goserelin in premenopausal Asian women with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from the randomized phase III MONALEESA-7 study
|
Im S.-A;Sohn J;Tripathy D;Chow L;Lee K.S;Jung K.H;Babu G;Im Y.-H;El Saghir N;Liu M.-C;Diaz-Padilla I;Alam J;Kong O;Miller M;Yen-Shen Lu; Im S.-A; Sohn J; Tripathy D; Chow L; Lee K.S; Jung K.H; Babu G; Im Y.-H; El Saghir N; Liu M.-C; Diaz-Padilla I; Alam J; Kong O; Miller M; YEN-SHEN LU |
